Skip to main content

Advertisement

SpringerLink
Log in

Pazopanib

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

 Pazopanib

In October 2009, pazopanib (Votrient; GlaxoSmithKline) — a multikinase inhibitor with targets that include vascular endothelial growth factor receptors — was approved by the US FDA for the treatment of advanced renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Targeting growth factor signalling in renal cell carcinoma.

References

  1. Garcia, J. A. & Rini, B. I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57, 112–125 (2007).

    Article  PubMed  Google Scholar 

  2. Atkins, M. A. et al. Everolimus. Nature Rev. Drug Discov. 8, 535–536 (2009).

    Article  CAS  Google Scholar 

  3. Heng, D. Y. & Bukowski, R. M. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr. Cancer Drug Targets 8, 676–682 (2008).

    Article  CAS  PubMed  Google Scholar 

  4. Harris, P. A. et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632–4640 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. Kumar, R. et al. Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6, 2012–2021 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. Food and Drug Administration. FDA labelling information. FDA website [online], (2009).

  7. Sternberg, C. N. et al. A randomized, double-blind phase lll study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 27, 15s A5021 (2009).

    Article  Google Scholar 

  8. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    Article  CAS  Google Scholar 

  9. Motzer, R. J. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516–2524, (2006).

    Article  CAS  Google Scholar 

  10. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).

    Article  CAS  Google Scholar 

  11. IMS MIDAS (IMS Health, 2009).

  12. SG Cowen Research Team. SG Cowen Therapeutic Categories Outlook (Sep 2009).

  13. Hauber, A., Vosser, R. & Evans, D. JP Morgan Equity Research Report (11 Sep 2009).

Download references

Author information

Authors and Affiliations

  1. Ronald M. Bukowski is at Cleveland Clinic Taussig Cancer Cente, Cleveland, Ohio, USA. bukow464@sbcglobal.net,

    Ronald M. Bukowski

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. UYasothan@de.imshealth.com,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Ronald M. Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R.M.B. has received honoraria and acted as a consultant for Pfizer, Novartis and Genentech, and has acted as a consultant for GSK and Bayer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bukowski, R., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat Rev Drug Discov 9, 17–18 (2010). https://doi.org/10.1038/nrd3073

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3073

  • Springer Nature Limited

This article is cited by

Search

Navigation